Abstract: The present application relates to the field of medicines, and in particular to an antibody-drug conjugate of a glucocorticoid receptor agonist. Specifically, the present application provides a glucocorticoid receptor agonist, which has good agonistic activity. The present application further provides a drug-linker compound for coupling, wherein the drug is a glucocorticoid receptor agonist. The present application further provides an antibody-drug conjugate prepared by coupling the drug-linker compound and the antibody, wherein the antibody-drug conjugate has good drug coupling uniformity, and has an excellent treatment effect on inflammatory diseases such as rheumatoid arthritis. The present application further provides a preparation method for the glucocorticoid receptor agonist and the antibody-drug conjugate thereof, and uses of the glucocorticoid receptor agonist and the antibody-drug conjugate thereof in the field of medicines.

Abstract: An adjustable angle spotlight structure is provided, which includes a lamp housing and a base, a plurality of through-holes are provided on a bottom side of the lamp housing, a circular sliding groove is provided on the lamp housing; a top of the base is fixedly provided with a lamp bead member, one side of the base is provided with locking posts; one side of the lamp bead member is extended to form a first stop edge, and a second stop edge is provided on an inner wall of the lamp housing, thereby forming a closed space with a built-in spring member. When adjusting, the base is pressed to disengage the locking posts from the through-holes and enter the sliding groove, the base is rotated to drive an optical lens to rotate, and the locking posts are slid to a target through-hole position, thereby achieving beam angle switching.

Abstract: A clamp slot structure includes a base and a lamp holder, an inner wall of a circular installation part on a back of the base is provided with two pairs of diagonally distributed wide edge clamp slots and narrow edge clamp slots, and the lamp holder is correspondingly provided with wide edge installation platforms and narrow edge installation platforms. During installation, the wide edge installation platforms are inserted vertically into the wide edge clamp slots after aligning, the lamp holder is rotated 90 degrees, and the wide edge installation platforms are clamped to a surface of an installation protrusion.

Abstract: The present disclosure relates to an antibody-drug conjugate (ADC) for treating CDH3-positive cancer. The ADCs have a CDH3 antibody and a drug-linker molecule conjugated to the antibody. The ADC of the present disclosure has a better drug-antibody conjugation ratio and a good, targeted killing effect on CDH3-positive cancer. Also provided is a preparation method of the antibody-drug conjugate and use thereof in the treatment of the CDH3-positive cancer.

Abstract: Provided are an HER3 binding protein and use thereof. Specifically, provided are an anti-HER3 antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and a method for preparing same. The anti-HER3 antibody or the antigen-binding fragment thereof has high specificity and high affinity for HER3 and does not bind to EGFR, HER2, and HER4 of the same family. Further provided is use of the antibody or the antigen-binding fragment thereof in the treatment and diagnosis of disease.

Abstract: The present application relates to an antibody-drug conjugate and a method for preparation and use thereof, and specifically relates to an antibody-drug conjugate for treating CEACAM5-positive cancer, including an anti-CEACAM5 antibody, and drug-linker molecules conjugated to the antibody. In some embodiments, the antibody is humanized. In some embodiments, the antibody has excellent binding activity to CEACAM5-positive cells, and can efficiently deliver drugs to CEACAM5-positive cells. In some embodiments, the drug includes a DNA topoisomerase inhibitor. The antibody-drug conjugate of the present application has a better drug-antibody conjugation ratio, and has a good targeted killing effect on certain cancers.

Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.

Abstract: The present application relates to an antibody-drug conjugate and its preparation methods and use, and specifically relates to an antibody-drug conjugate for treating HER3-positive cancers. The present application provides a fully human HER3 antibody, which has excellent binding activity to HER3-positive cells and can efficiently deliver drugs to HER3-positive cells. The present application also provides a drug-linker molecule coupled to the antibody, and the drug comprises a DNA topoisomerase inhibitor. The obtained antibody-drug conjugate has a better drug-to-antibody ratio, and has a good targeted killing effect on colon cancer, gastric cancer, breast cancer, and lung cancer (e.g., non-small cell lung cancer, specifically, lung adenocarcinoma). Therefore, the present application further provides a preparation method for the antibody-drug conjugate and application of the antibody-drug conjugate in the treatment of a HER3-positive cancer.

Abstract: Antibody-drug conjugates (ADC) useful for preventing, treating, and/or acting as an adjuvant in treating c-MET and/or EGFR-related diseases are disclosed. The ADCs comprise a bispecific antibody or antigen-binding fragment thereof comprising an arm specific for binding to EGFR and an arm specific for binding to c-MET conjugated to a cytotoxic drug.

Abstract: Provided herein is an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding the antibody and fragment, and method for preparing the antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Also provided herein is a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs for the prevention and/or treatment of tumors.

Abstract: The present invention is applicable to the technical field of lamp products, and provides a multi-angle adjustable spot-flood light, comprising a lamp holder, a light source, an optical assembly and an angle adjustment mechanism. Wherein the optical assembly comprises a first optical lens and a second optical lens spaced from and parallel to the first optical lens, a first optical structure is arranged on a light-emitting surface of the first optical lens, and a second optical structure is arranged on a light incident surface of the second optical lens. The angle adjustment mechanism comprises a first lens holder fixedly connected to the lamp holder and a second lens holder rotatable relative to the first lens holder, the first optical lens is fixed on the first lens holder, and the second optical lens is fixed on the second lens holder.

Abstract: The present invention is applicable to the technical field of lamp products, and provides a multi-angle adjustable spot-flood light, comprising a lamp holder, a light source, an optical assembly and an angle adjustment mechanism. Wherein the optical assembly comprises a first optical lens and a second optical lens spaced from and parallel to the first optical lens, a first optical structure is arranged on a light-emitting surface of the first optical lens, and a second optical structure is arranged on a light incident surface of the second optical lens. The angle adjustment mechanism comprises a first lens holder fixedly connected to the lamp holder and a second lens holder rotatable relative to the first lens holder, the first optical lens is fixed on the first lens holder, and the second optical lens is fixed on the second lens holder.

Abstract: The present disclosure discloses a thermal plasma treatment method for sulfur hexafluoride (SF6) degradation. In the thermal plasma treatment method for SF6 degradation, Ar is input into a thermal plasma generator as a carrier gas; annular electrodes are electrically connected to a direct current power supply to generate an arc plasma region in the presence of the carrier gas Ar; to-be-reacted SF6 and to-be-reacted H2 in a predetermined ratio are input into the arc plasma region to generate hydrogen radicals as well as fluorine radicals, and the hydrogen radicals and the fluorine radicals are bonded with each other to generate HF to inhibit the self-recovery reaction of SF6; and final products include HF and elemental S.

Abstract: The present disclosure discloses a thermal plasma treatment method for sulfur hexafluoride (SF6) degradation. In the thermal plasma treatment method for SF6 degradation, Ar is input into a thermal plasma generator as a carrier gas; annular electrodes are electrically connected to a direct current power supply to generate an arc plasma region in the presence of the carrier gas Ar; to-be-reacted SF6 and to-be-reacted H2 in a predetermined ratio are input into the arc plasma region to generate hydrogen radicals as well as fluorine radicals, and the hydrogen radicals and the fluorine radicals are bonded with each other to generate HF to inhibit the self-recovery reaction of SF6; and final products include HF and elemental S.

Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.

Abstract: This disclosure provides systems, methods, and apparatus related to acoustic transducers.

Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.

Abstract: This disclosure provides systems, methods, and apparatus related to acoustic transducers.

Abstract: A solid-state, low power microheater sensor platform that is configurable with selected metal oxide films for particular gas sensing applications is described. The sensor platform is configured by selecting a chemiresistive or catalytic material that is suitable for detecting a desired gas and then forming a porous nanostructured film on the designated surfaces of the microheater platform. Also described are methods for creating a highly porous, nanostructured metal oxide film in a controlled location from a liquid precursor using a localized heat source. By fast annealing deposited liquid precursors with the microheater, a highly porous, nanocrystalline metal oxide film can be generated in-situ and locally on the sensor platform.

Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.